Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy (Q45098501)

9 December 2017

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy (English)

1 reference

9 December 2017

Wright GL Jr

1

1 reference

9 December 2017

Grob BM

2

1 reference

9 December 2017

Haley C

3

1 reference

9 December 2017

Grossman K

4

1 reference

9 December 2017

Newhall K

5

1 reference

9 December 2017

Petrylak D

6

1 reference

9 December 2017

Troyer J

7

1 reference

9 December 2017

Konchuba A

8

1 reference

9 December 2017

Schellhammer PF

9

1 reference

9 December 2017

Moriarty R

10

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 August 1996

1 reference

9 December 2017

1 reference

9 December 2017

48

1 reference

9 December 2017

326-334

1 reference

9 December 2017

2

1 reference

Endocrine therapy in carcinoma of the prostate gland: 10-year survival studies

9 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Endocrine Therapy for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Pathologic changes associated with androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

The promoter of the prostate-specific antigen gene contains a functional androgen responsive element

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Hormonal regulation of transforming growth factor beta-2 expression in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Activation of programmed cell death in the rat ventral prostate after castration

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

A pilot trial of chemohormonal therapy for metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2900184-7

7 January 2021

10.1016/S0090-4295(96)00184-7

Identifiers

DOI

1 reference

release_klin2k7e5bephfsbh5bvjjtgti

9 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/klin2k7e5bephfsbh5bvjjtgti

24 November 2022

mapped directly with Wikidata item

1 reference